BACKGROUND: Cardiovascular disease is the leading cause of morbidity and mortality among patients with diabetes, underscoring the importance of choosing drugs that do not increase cardiovascular risk and reduce the risk of cardiovascular events. Since 2008, the US Food and Drug Administration has recommended that new drugs for type 2 diabetes undergo clinical trials to demonstrate cardiovascular safety in addition to glycemic benefit. In 2012, the European Medicines Agency issued a similar recommendation. METHODS: We searched the PubMed, Cochrane CENTRAL, EMBASE, and CINAHL databases from inception through August 2013 and compiled and reviewed the existing data on the cardiovascular safety profiles of currently available diabetic drugs. RESULTS: While intensive glycemic control in diabetics has been consistently shown to reduce the risk of microvascular complications, the data on macrovascular risk reduction have not been as clear, and questions have been raised about possible increases in cardiovascular morbidity and mortality. CONCLUSION: Careful selection of drug therapy-paying particular attention to cardiovascular safety-is important in optimizing diabetic therapy.
BACKGROUND:Cardiovascular disease is the leading cause of morbidity and mortality among patients with diabetes, underscoring the importance of choosing drugs that do not increase cardiovascular risk and reduce the risk of cardiovascular events. Since 2008, the US Food and Drug Administration has recommended that new drugs for type 2 diabetes undergo clinical trials to demonstrate cardiovascular safety in addition to glycemic benefit. In 2012, the European Medicines Agency issued a similar recommendation. METHODS: We searched the PubMed, Cochrane CENTRAL, EMBASE, and CINAHL databases from inception through August 2013 and compiled and reviewed the existing data on the cardiovascular safety profiles of currently available diabetic drugs. RESULTS: While intensive glycemic control in diabetics has been consistently shown to reduce the risk of microvascular complications, the data on macrovascular risk reduction have not been as clear, and questions have been raised about possible increases in cardiovascular morbidity and mortality. CONCLUSION: Careful selection of drug therapy-paying particular attention to cardiovascular safety-is important in optimizing diabetic therapy.
Authors: Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz Journal: N Engl J Med Date: 2013-09-02 Impact factor: 91.245
Authors: Despoina Vasilakou; Thomas Karagiannis; Eleni Athanasiadou; Maria Mainou; Aris Liakos; Eleni Bekiari; Maria Sarigianni; David R Matthews; Apostolos Tsapas Journal: Ann Intern Med Date: 2013-08-20 Impact factor: 25.391
Authors: K Hermansen; T A Bækdal; M Düring; A Pietraszek; L S Mortensen; H Jørgensen; A Flint Journal: Diabetes Obes Metab Date: 2013-06-11 Impact factor: 6.577
Authors: Y Ohkubo; H Kishikawa; E Araki; T Miyata; S Isami; S Motoyoshi; Y Kojima; N Furuyoshi; M Shichiri Journal: Diabetes Res Clin Pract Date: 1995-05 Impact factor: 5.602
Authors: Willemien J Kruik-Kollöffel; Enriqueta Vallejo-Yagüe; Kris L L Movig; Gerard C M Linssen; Edith M Heintjes; Job van der Palen Journal: Int J Clin Pharm Date: 2022-05-28
Authors: Lale Ozcan; Canan Kasikara; Arif Yurdagul; George Kuriakose; Brian Hubbard; Michael H Serrano-Wu; Ira Tabas Journal: PLoS One Date: 2021-05-13 Impact factor: 3.240
Authors: Victoria Petri; G Thomas Hayman; Marek Tutaj; Jennifer R Smith; Stan Laulederkind; Shur-Jen Wang; Rajni Nigam; Jeff De Pons; Mary Shimoyama; Melinda R Dwinell Journal: Comput Struct Biotechnol J Date: 2015-11-26 Impact factor: 7.271